MedTrace Logo

Comparison of Bupivacaine and Exparel for Carpal Tunnel Release

NCT02141178 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-01-05

No results posted yet for this study

Summary

Carpal tunnel syndrome is one of the most common surgeries performed per year in the United States, accounting for over 600,000 surgeries. The procedure is commonly performed under light sedation and local anesthesia. Bupivicaine, a long acting local anesthetic, has been used to allow extended pain relief for 8-10 hours after carpal tunnel release. Exparel, a liposomal bupivicaine formulation, has been documented to provide pain relief for up to 72 hours post-operatively. By decreasing post-operative pain through the use of a long-acting local anesthetic, the use of narcotic pain medications may be decreased and patient satisfaction scores may increase.

The purpose of this study is to prospectively compare bupivicaine and liposomal bupivicaine with respect to post-operative pain control, narcotic usage, and patient satisfaction after carpal tunnel release.

Conditions

  • Pain After Carpal Tunnel Release

Interventions

DRUG

Bupivacaine

DRUG

Exparel

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02141178 on ClinicalTrials.gov